Nebulized Colistin Dosing
For nebulized colistin in adults, administer 75 mg of colistin base activity (equivalent to approximately 2.5 million IU of colistimethate sodium) every 12 hours as adjunctive therapy to systemic antibiotics for ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria.
Adult Dosing
The evidence supports nebulized colistimethate sodium at 75 mg colistin base activity (approximately 2.5 million IU CMS) diluted in 4 mL of normal saline, administered every 12 hours 1. This regimen has been studied in randomized controlled trials for ventilator-associated pneumonia and demonstrated:
- Significantly improved microbiological outcomes (60.9% vs 38.2% bacterial clearance, p=0.03)
- Acceptable safety profile with bronchospasm in only 7.8% of patients
- Low systemic absorption, minimizing nephrotoxicity risk
- Should be continued until systemic antibiotic therapy is completed
Important caveat: While nebulized colistin improved microbiological clearance, it did not significantly improve clinical outcomes in the pivotal trial (51% vs 53.1%, p=0.84) 1. This suggests it should be used as adjunctive therapy only, not as monotherapy.
Pediatric/Neonatal Dosing
For mechanically ventilated neonates, 120,000 IU/kg (equivalent to 4 mg/kg colistin base activity) administered every 12 hours achieved therapeutic tracheal aspirate concentrations for at least 12 hours with minimal systemic absorption 2. Key pharmacokinetic findings:
- Tracheal aspirate Cmax: 24.0 ± 8.2 μg/mL
- Half-life: 9.8 ± 5.5 hours
- Plasma concentrations remained low, reducing systemic toxicity risk
- Twice-daily dosing is appropriate based on the prolonged local half-life
Critical Considerations
Renal Function Monitoring
Renal function must be monitored closely during any colistin therapy 3. While nebulized colistin has minimal systemic absorption compared to IV administration, patients receiving concomitant systemic colistin or other nephrotoxic agents require particular vigilance. Acute kidney injury is a major factor related to clinical failure and mortality with colistin therapy 3.
Bronchospasm Risk
Monitor for bronchospasm during nebulization (occurs in approximately 8% of patients) 1. Have bronchodilators readily available and consider pre-treatment with inhaled beta-agonists in patients with reactive airway disease.
Combination with Systemic Therapy
Nebulized colistin should always be combined with appropriate systemic antibiotics based on susceptibility testing 1. The evidence does not support nebulized colistin as standalone therapy for pneumonia.
Preparation and Administration
- Reconstitute colistimethate sodium powder with sterile water to appropriate concentration
- Dilute in 4 mL normal saline for nebulization
- Use freshly prepared solutions
- Administer via standard nebulizer connected to ventilator circuit in mechanically ventilated patients
When NOT to Use Nebulized Colistin
The evidence provided focuses on ventilator-associated pneumonia in mechanically ventilated patients. There is insufficient evidence to recommend nebulized colistin for non-ventilated patients or non-pulmonary infections. For systemic infections, IV colistin remains the standard route 4.